Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,200.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective increased by equities researchers at Barclays from $1,050.00 to $1,200.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 11.08% from the company’s […]
More Stories
491 Fugitives Hiding in Public Housing Arrested in Nationwide Sweep
By Naveen Athrappully A multi-month law enforcement operation has led to the arrests of 491 criminal fugitives living in government-assisted...
Trump Doubles Down on $5,000 Payments Tied to Midterm Results
By Jack Phillips President Donald Trump on Monday released a new advertisement that doubled down on his promise to send...
Zelenskyy Says Strikes on Russian Refineries Will Continue If Putin Rejects Energy Ceasefire
By Owen Evans Ukraine will continue its long-range strikes against Russia if Moscow doesn’t accept an energy truce, President Volodymyr...
Federal Agents Search Rep. Ilhan Omar’s Home: What We Know
By Jack Phillips The Washington home of Rep. Ilhan Omar (D-Minn.) was searched on Monday by federal agents as part...
Federal Agents Search Rep. Ilhan Omar’s Home: AP Report
By Zachary Stieber Federal agents on Oct. 12 searched the home of Rep. Ilhan Omar (D-Minn.) as part of a...
30-Year Fixed-Rate Mortgage Rate Hits 7.4 percent
By Naveen Athrappully The average weekly rate on a 30-year fixed-rate mortgage hit 7.4 percent, according to a Oct. 8...